32
Views
0
CrossRef citations to date
0
Altmetric
Review

Radioembolization for colorectal cancer liver metastases: current role and future opportunities – the medical oncologist’s perspective

, &
Pages 345-362 | Published online: 13 Oct 2014

References

  • Weiss L , GrundmannE, TorhorstJet al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J. Pathol.150(3), 195–203 (1986).
  • Bentrem DJ , DeMatteoRP, BlumgartLH. Surgical therapy for metastatic disease to the liver. Annu. Rev. Med.56, 139–156 (2005).
  • Nagorney, DM, Gigot, JF. Primary epithelial hepatic malignancies: etiology, epidemiology, and outcome after subtotal and total hepatic resection. Surg. Oncol. Clin. N. Am.5, 283–300 (1996).
  • Fernandez FG , DrebinJA, LinehanDC, DehdashtiF, SiegelBA, StrasbergSM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann. Surg.240, 438–447 (2004).
  • Adam R . Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann. Oncol.14(Suppl. 2), ii13–ii16 (2003).
  • Abdalla EK , VautheyJN, EllisLMet al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann. Surg.239(6), 818–825 (2004).
  • Adam R , AvisarE, AricheAet al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann. Surg. Oncol.8(4), 347–353 (2001).
  • Adams RB , AloiaTA, LoyerE, PawlikTM, TaouliB, VautheyJN. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford)15(2), 91–103 (2013).
  • Garden OJ , ReesM, PostonGJet al. Guidelines for resection of colorectal cancer liver metastases. Gut55(Suppl. 3), iii1–iii8 (2006).
  • NCCN Guidelines Version 3, 2013: colon cancer. www.nccn.org.
  • NCCN Guidelines Version 1, 2014: rectal cancer. www.nccn.org.
  • Giacchetti S , ItzhakiM, GruiaGet al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann. Oncol.10, 663–669 (1999).
  • Adam R , DelvartV, PascalGet al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann. Surg.240, 644–657 (2004).
  • de Haas RJ , WichertDA, SalloumCet al. Long-term outcomes after hepatic resection for colorectal metastases in young patients. Cancer116, 647–658 (2010).
  • Nordlinger B , Van CutsemE, RougierPet al. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur. J. Cancer43, 2037–2045 (2007).
  • Kennedy AS , NuttingC, ColdwellD, GaiserJ, DrachenbergC. Pathologic response and microdosimetry of 90Y microspheres in man: review of four explanted whole livers. Int. J. Radiat. Oncol. Biol. Phys.60(5), 1552–1563 (2004).
  • Kennedy A , ColdwellD, SangroB, WasanH, SalemR. Radioembolization for the treatment of liver tumors general principles. Am. J. Clin. Oncol.35(1), 91–99 (2012).
  • Salem R , LewandowskiRJ. Chemoembolization and radioembolization for hepatocellular carcinoma. Clin. Gastroenterol. Hepatol.11, 604–611 (2013).
  • Bilbao JI , de MartinoA, de LuisEet al. Biocompatibility, inflammatory response, and recannalization characteristics of nonradioactive resin microspheres: histological findings. Cardiovasc. Intervent. Radiol.32(4), 727–736 (2009).
  • Wang LM , JaniAR, HillEJ, SharmaRA. Anatomical basis and histopathological changes resulting from selective internal radiotherapy for liver metastases. J. Clin. Pathol.66(3), 205–211 (2013).
  • Wang S-C , BesterL, BurnesJPet al. Clinical care and technical recommendations for 90yttrium microsphere treatment of liver cancer. J. Med. Imag. Radiat. Oncol.54, 178–187 (2010).
  • Gray B , Van HazelG, HopeMet al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann. Oncol.12(12), 1711–1720 (2001).
  • Van Hazel G , BlackwellA, AndersonJet al. Randomised Phase II trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J. Surg. Oncol.88(2), 78–85 (2004).
  • Sharma RA , Van HazelGA, MorganBet al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J. Clin. Oncol.25, 1099–1106 (2007).
  • Kosmider S , TanT, YipD, DowlingR, LichtensteinM, GibbsP. Radioembolization in combination with systemic chemotherapy as firstline therapy for liver metastases from colorectal cancer. J. Vasc. Interv. Radiol.22, 780–786 (2011).
  • Van Hazel GA , PavlakisN, GoldsteinDet al. Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J. Clin. Oncol.27, 4089–4095 (2009).
  • Lim L , GibbsP, YipDet al. A prospective evaluation of treatment with selective internal radiation therapy (SIR-Spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer5, 132–137 (2005).
  • Hendlisz A , Van den EyndeM, PeetersMet al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J. Clin. Oncol.28(23), 3687–3694 (2010).
  • Seidensticker R , DeneckeT, KrausPet al. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc. Intervent. Radiol.35, 1066–1073 (2012).
  • Bester L . Radioembolization versus standard care of hepatic metastases: comparative retrospective cohort study of survival outcomes and adverse events in salvage patients. J. Vasc. Interv. Radiol.23, 96–105 (2012).
  • Cosimelli M , GolfieriR, CagolPet al. Multi-centre Phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br. J. Cancer103, 324–331 (2010).
  • Nace GW , SteelJL, AmesurNet al. Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience. Int. J. Surg. Oncol. 2011, 571261 (2011).
  • Cianni R , UrigoC, NotarianniEet al. Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases. Cardiovasc. Intervent. Radiol.32, 1179–1186 (2009).
  • Jakobs TS , HoffmannR-T, DehmKet al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J. Vasc. Interv. Radiol.19, 1187–1195 (2008).
  • Kennedy AS , ColdwellD, NuttingCet al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int. J. Radiat. Oncol. Biol. Phys.65(2), 412–425 (2006).
  • Sofocleous CT , GarciaAR, Pandit-TaskarNet al. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. Clin. Colorectal Cancer13, 27–36 (2014).
  • Sangro B , ChopiteaA, RodriguezAet al. Radioembolization using yttrium-90 resin microspheres as consolidation treatment after first-line chemotherapy for liver metastases from colorectal cancer. Presented at:ASCO Gastrointestinal Cancers Symposium 2010.Orlando, FL, USA, 22–24 January 2010 (Abstract 250).
  • Goldberg RM , SargentDJ, MortonRFet al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol.22, 23–30 (2004).
  • Tournigand C , CervantesA, FigerAet al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer – a GERCOR study. J. Clin. Oncol.24(3), 394–400 (2006).
  • de Gramont A , FigerA, SeymourM. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol.18, 2938–2947 (2000).
  • Kalofonos HP , AravantinosG, KosmidisPet al. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, Phase II study. Ann. Oncol.16(6), 869–877 (2005).
  • Gulec SA , PenningtonK, WheelerJet al. Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled Phase II trial. Am. J. Clin. Oncol.36(5), 455–460 (2012).
  • Bester L , MetelingB, PocockN, SaxenaA, ChuaTC, MorrisDL. Radioembolisation with yttrium-90 microspheres: an effective treatment modality for unresectable liver metastases. J. Med. Imaging Radiat. Oncol.57, 72–80 (2013).
  • Van den Eynde M , FlamenP, El NakadiIet al. Inducing resectability of chemotherapy refractory colorectal liver metastasis by radioembolization with yttrium-90 microspheres. Clin. Nucl. Med.33, 697–699 (2008).
  • Hoffmann RT , JakobsTF, KubischHJet al. Radiofrequency ablation after selective internal radiation therapy with Yttrium90 microspheres in metastatic liver disease – is it feasible? Eur. J. Radiol. 74, 199–205 (2010).
  • Chua T , BesterL, AktherJ, MorrisD. Successful right hepatectomy after four treatments of yttrium-90 microspheres (SIR-Spheres) and concomitant FOLFOX as bridging therapy to resection of colorectal liver metastases. Anticancer Res.30, 3005–3007 (2010).
  • Whitney R , Cliff TatumBS, HahlMet al. Safety of hepatic resection in metastatic disease to the liver after yttrium-90 therapy. J. Surg. Res.166, 236–240 (2011).
  • Folprecht G , GrotheyA, AlbertsS, RaabHR, KöhneCH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann. Oncol.16(8), 1311–1319 (2005).
  • Chua TC , BesterL, SaxenaA, MorrisDL. Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. J. Cancer Res. Clin. Oncol.137(5), 865–873 (2011).
  • Mulcahy MF , LewandowskiRJ, IbrahimSMet al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer115, 1849–1858 (2009).
  • Dunfee BL , RiazA, LewandowskiRJet al. Yttrium-90 radioembolization for liver malignancies: prognostic factors associated with survival. J. Vasc. Intervent. Radiol.21(1), 90–95 (2010).
  • Iñarrairaegui M, Bilbao JI, RodríguezM, BenitoA, SangroB. Liver radioembolization using 90Y resin microspheres in elderly patients: tolerance and outcome. Hosp. Pract. (Minneapolis)38(5), 103–109 (2010).
  • Kennedy A , NagS, SalemRet al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the Radioembolization Brachytherapy Oncology Consortium. 2007Int. J. Radiat. Oncol. Biol. Phys.68(1), 13–23 (2007).
  • Gil-Alzugaray B , ChopiteaA, IñarrairaeguiMet al. Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology57(3), 1078–1087 (2013).
  • Sangro B , Gil-AlzugarayB, RodriguezJet al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer112(7), 1538–1546 (2008).
  • Riaz J , LewandowskiRJ, KulikLMet al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J. Vasc. Interv. Radiol.20, 1121–1130 (2009).
  • Atassi B , BangashAK, LewandowskiRJet al. Biliary sequelae following radioembolization with Yttrium-90 microspheres. J. Vasc. Interv. Radiol.19(5), 691–697 (2008).
  • Nicolay NH , BerryDP, SharmaRA. Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat. Rev. Clin. Oncol.6(12), 687–697 (2009).
  • Murthy R , NunezR, SzklarukJet al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics.25 (Suppl. 1), S41–S55 (2005).
  • Lam MG , BanerjeeS, LouieJDet al. Root cause analysis of gastroduodenal ulceration after yttrium-90 radioembolization. Cardiovasc. Intervent. Radiol.36(6), 1536–1547 (2013).
  • Kennedy AS , McNeillieP, DezarnWAet al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int. J. Radiat. Oncol. Biol. Phys.74(5), 1494–1500 (2009).
  • Seidensticker R , SeidenstickerM, DammRet al. Hepatic toxicity after radioembolization of the liver using 90Y-microspheres: sequential lobar versus whole liver approach. Cardiovasc. Intervent. Radiol.35, 1109–1118 (2012).
  • Lam MG , LouieJD, IagaruAH, GorisML, SzeDY. Safety of repeated yttrium-90 radioembolization. Cardiovasc. Intervent. Radiol.36(5), 1320–1328 (2013).
  • Nosher JL , Ohman-StricklandPA, JabbourS, NarraV, NosherB. Changes in liver and spleen volumes and liver function after radioembolization with yttrium-90 resin microspheres. J. Vasc. Interv. Radiol.22, 1706–1713 (2011).
  • Lim L , GibbsP, YipDet al. Prospective study of treatment with selective internal radiation therapy spheres in patients with unresectable primary or secondary hepatic malignancies. Int. Med. J.35, 222–227 (2005).
  • Stubbs RS , O’BrienI, CorreiaMM. Selective internal radiation therapy with 90Y microspheres for colorectal liver metastases: single-centre experience with 100 patients. ANZ J. Surg.76(8), 696–703 (2006).
  • Coldwell D , SangroB, WasanH, SalemR, KennedyA. General selection criteria of patients for radioembolization of liver tumors: an international working group report. Am. J. Clin. Oncol.34, 337–341 (2011).
  • Bester L , FeitelsonS, MilnerB, ChuaTC, MorrisDL. Impact of prior hepatectomy on the safety and efficacy of radioembolization with yttrium-90 microspheres for patients with unresectable liver tumors. Am. J. Clin. Oncol.37(5), 454–460 (2014).
  • Brown RE , BowerMR, MetzgerTLet al. Hepatectomy after hepatic arterial therapy with either yttrium-90 or drug-eluting bead chemotherapy: is it safe? HPB (Oxford) 13(2), 91–95 (2011).
  • Atassi B , BangashAK, BahraniAet al. Multimodality imaging following 90Y radioembolization: a comprehensive review and pictorial essay. RadioGraphics28, 81–99 (2008).
  • Miller FH , KeppkeAL, ReddyDet al. Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR Am. J. Roentgenol.188(3), 776–783 (2007).
  • Kennedy A , KreukP, JakobsT, DezarnW. Effects of anti-angiogenic therapy and chemotherapy on 90Y-microsphere treatment of colorectal liver metastases. Presented at:20th International Congress on Anti Cancer Treatment (ICACT).Paris, France, 3–6 February 2009 (Abstract IC/AB159).
  • ClinicalTrials.gov . http://clinicaltrials.gov/show/NCT00724503.
  • ISRCTN Register . http://www.controlled-trials.com/ISRCTN83867919.
  • ClinicalTrials.gov .http://clinicaltrials.gov/show/NCT01721954.
  • ClinicalTrials.gov . http://clinicaltrials.gov/show/NCT01895257.
  • ClinicalTrials.gov .http://clinicaltrials.gov/show/NCT01098422.
  • SIRTEX . Ongoing clinical studies. http://www.sirtex.com.au/eu/clinicians/ongoing-clinical-studies.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.